telemedicine adoption nationally among the commercially insured. To address this gap, we examined trends in telemedicine use and its association with regional factors (parity legislation and physician supply) within a large commercial health plan.
Methods | We used 2005-2017 data from OptumLabs Data Warehouse, a deidentified claims database for privately insured and Medicare Advantage enrollees in a large, private US health plan. Database enrollees are younger and more concentrated in the South compared with the overall US population. Telemedicine visits were identified using Medicare criteria 3 and grouped into 3 categories: telemental health (visits with mental health clinicians, mental health-specific Current Procedural Terminology codes, or primary mental health diagnoses), primary care telemedicine (non-telemental health visits with primary care clinicians), and other telemedicine (all remaining specialist visits).
We estimated growth in telemedicine use from 2005 to 2017 using a regression model with a linear variable for time and log-transformed telemedicine visit volume as the dependent variable. We examined trends in telemedicine use stratified by state parity laws 4 and countylevel physician supply. Using separate multivariable regression with the dependent variable of telemedicine visits per 1000 enrollees, we examined linear indicators for time interacted with presence of parity law and level of physician supply to estimate differences in trends between categories. All statistical analyses were performed in R version 3.5.0 (R Project for Statistical Computing), with 2-sided P < .05 considered significant. The Harvard Medical School institutional review board exempted this study from review. Figure) . Most telemedicine visits were either telemental health (53%) or primary care telemedicine (39%). Primary care telemedicine visits grew 36% annually before 2016 and then increased sharply to 136 366 visits in 2017, while telemental health grew 56% annually to 57 095 visits in 2017. By 2017, primary care telemedicine was the most frequently used form of telemedicine.
Results
Use of telemental health increased significantly faster in counties with no psychiatrists (P < .001 for interaction) ( Figure) and in states with comprehensive parity mandates (P = .02 for interaction). In contrast, growth of primary care telemedicine was not associated with primary care physician supply (P = .76 for interaction), and there was a small negative association with comprehensive parity laws (P = .04 for interaction).
Discussion | Although telemedicine use increased substantially from 2005 to 2017, use was still uncommon by 2017. Use of telemental health grew steadily over this period. In contrast, there was a rapid increase in growth for primary care telemedicine in 2016 and 2017 after coverage for direct-to-consumer telemedicine expanded. 5, 6 An important limitation is that these data are from a single insurer whose population and policies may not generalize to other populations. In this sample, telemedicine for subspecialty care beyond mental health was uncommon, and despite the attention given to telemedicine for rural settings, most telemedicine users lived in urban areas. Physician supply appears to be influential for telemental health but not for primary care telemedicine, the brisk adoption of which may reflect consumers seeking convenience rather than reflecting low primary care supply. This evidence suggests that local coverage and reimbursement regulations may have influenced growth of telemental care but not primary care telemedicine. 
Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017
The gabapentinoid drugs gabapentin and pregabalin are approved for epilepsy, neuropathic pain, migraines (gabapentin only), and generalized anxiety disorders (pregabalin only) in the United Kingdom. These indications differ in other countries. Gabapentinoid prescriptions increased in the United States between 2002 and 2015, 1 which may be partly related to an increase in off-label use. 2 These medications have the potential for misuse and addiction and for overdose, when used in combination with opioids. 3 In 2017, the UK government reclassified gabapentinoids as class C controlled substances. 4 We estimated the rates of patients treated with gabapentin and pregabalin for the first time in the UK primary care system since these drugs were first licensed in 1993 and 2004, respectively.
Methods | Using the Clinical Practice Research Datalink (CPRD), a UK database of primary care medical records from more than 15 million patients, 5 we identified all patients registered for at least 1 day between 1993 and 2017, with follow-up starting on January 1, 1993, or the patient's registration date with the practice, whichever came later. Follow-up ended at the date the patient transferred out of the practice, the date of the patient's death, or December 31, 2017, whichever occurred first. We used Poisson regression to estimate the annual rates of patients newly treated with gabapentin and pregabalin, separately, estimating rate ratios (RRs) over the last 10 years. For each patient with a first prescription, we identified same-day prescriptions for opiates and/or benzodiazepines (including sedatives). We inferred the indication corresponding to their first prescription using relevant diagnostic codes up to 1 year before this first prescription. Indication was classified in a hierarchical manner into 1 of 3 mutually exclusive categories: approved, off-label (nonneuropathic pain, other), or unknown. The study protocol was approved by the Independent Scientific Advisory Committee of the CPRD and the research ethics committee of the Jewish General Hospital, which also waived the need for patient informed consent. All analyses were conducted with SAS, version 9.4 (SAS Institute Inc).
Results | From 12 512 468 patients, we identified 256 410 (2.0%) who were newly treated with gabapentin and 136 653 (1.1%) with pregabalin. From 2007 to 2017, the rate of patients newly treated increased from 230 to 679 per 100 000 persons per year for gabapentin (RR, 2.95 [95% CI, ) and from 128 to 379 per 100 000 persons per year for pregabalin (RR, 2.96 [95% CI, .05]) (Figure 1) . The rate of patients with a coprescription for opioids and/or benzodiazepines also increased from 56.4 to 148.1 per 100 000 persons per year for gabapentin (RR, 2.62 [95% CI, 2.50-2.76]) and from 28.7 to 91.2 per 100 000 persons per year for pregabalin (RR, 3.18 [95% CI, ). In 2017, 21.8% of patients newly treated with gabapentin and 24.1% newly treated with pregabalin received a concomitant prescription, primarily for opioids.
We identified a prescription indication for 64.2% of patients newly treated with gabapentin and 63.2% of patients newly treated with pregabalin. The rate of patients with an offlabel indication increased from 58.7 to 216.0 per 100 000 persons per year for gabapentin (RR, 3.68 [95% CI, ) and from 34.7 to 117.8 per 100 000 persons per year for pregabalin (RR, 3.40 [95% CI, .60]) (Figure 2) . Off-label prescriptions accounted for 52.0% of gabapentin and 54.8% of pregabalin prescriptions with an identified indication in 2017. Nonneuropathic pain accounted for 80.4% of gabapentin and 58.3% of pregabalin off-label prescriptions.
Discussion | The rate of patients newly treated with gabapentinoids has tripled from 2007 to 2017 in primary care in the United Kingdom. By 2017, 50% of gabapentinoid prescriptions were for an off-label indication and 20% had a coprescription for opioids.
The study had some limitations. Prescription indications were inferred from patients' medical history. An indication was identified for 60% of all patients newly treated because indications are not systematically recorded in the CPRD for each issued prescription, which could lead to misclassification. Also, only primary care practices were included. However, as general practitioners are central to the UK health system, most gabapentinoid prescriptions were likely issued by general practitioners, even when the treatment was initiated by a specialist. 
